Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy

Gregor Schweighofer-Zwink; Reyhaneh Manafi-Farid; Peter Kölblinger; Lukas Hehenwarter; Sara Harsini; Christian Pirich; Mohsen Beheshti

doi:10.1016/j.ejrad.2021.110107

Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy

Gregor Schweighofer-Zwink (First author)
, Reyhaneh Manafi-Farid
, Peter Kölblinger (Co-author)
, Lukas Hehenwarter (Co-author)
, Sara Harsini
, Christian Pirich (Co-author)
, Mohsen Beheshti^* (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article › peer-review

16 Citations (Web of Science)

Original language	English
Pages (from-to)	110107
Journal	EUROPEAN JOURNAL OF RADIOLOGY
Volume	146
DOIs	https://doi.org/10.1016/j.ejrad.2021.110107
Publication status	Published - 2022

Keywords

IMMUNE-RELATED RESPONSE
CUTANEOUS MELANOMA
F-18-FDG PET/CT
POOLED ANALYSIS
OPEN-LABEL
IPILIMUMAB
SURVIVAL
PEMBROLIZUMAB
NIVOLUMAB
PHASE-3

Access to Document

10.1016/j.ejrad.2021.110107

Cite this

Schweighofer-Zwink, G., Manafi-Farid, R., Kölblinger, P., Hehenwarter, L., Harsini, S., Pirich, C., & Beheshti, M. (2022). Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy . EUROPEAN JOURNAL OF RADIOLOGY , 146, 110107. https://doi.org/10.1016/j.ejrad.2021.110107

Schweighofer-Zwink, Gregor ; Manafi-Farid, Reyhaneh ; Kölblinger, Peter et al. / Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy . In: EUROPEAN JOURNAL OF RADIOLOGY 2022 ; Vol. 146. pp. 110107.

@article{3fa23d56b5454d4083ccb3e00a9a22c9,

title = "Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy ",

keywords = "IMMUNE-RELATED RESPONSE, CUTANEOUS MELANOMA, F-18-FDG PET/CT, POOLED ANALYSIS, OPEN-LABEL, IPILIMUMAB, SURVIVAL, PEMBROLIZUMAB, NIVOLUMAB, PHASE-3",

author = "Gregor Schweighofer-Zwink and Reyhaneh Manafi-Farid and Peter K{\"o}lblinger and Lukas Hehenwarter and Sara Harsini and Christian Pirich and Mohsen Beheshti",

note = "Schweighofer-Zwink; Hehenwarter; Pirich; Beheshti: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria; K{\"o}lblinger: Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria",

year = "2022",

doi = "10.1016/j.ejrad.2021.110107",

language = "English",

volume = "146",

pages = "110107",

journal = "EUROPEAN JOURNAL OF RADIOLOGY ",

issn = "0720-048X",

}

Schweighofer-Zwink, G, Manafi-Farid, R, Kölblinger, P , Hehenwarter, L, Harsini, S, Pirich, C & Beheshti, M 2022, 'Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy ', EUROPEAN JOURNAL OF RADIOLOGY , vol. 146, pp. 110107. https://doi.org/10.1016/j.ejrad.2021.110107

Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy . / Schweighofer-Zwink, Gregor (First author); Manafi-Farid, Reyhaneh; Kölblinger, Peter (Co-author) et al.
In: EUROPEAN JOURNAL OF RADIOLOGY , Vol. 146, 2022, p. 110107.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy

AU - Schweighofer-Zwink, Gregor

AU - Manafi-Farid, Reyhaneh

AU - Kölblinger, Peter

AU - Hehenwarter, Lukas

AU - Harsini, Sara

AU - Pirich, Christian

AU - Beheshti, Mohsen

N1 - Schweighofer-Zwink; Hehenwarter; Pirich; Beheshti: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria; Kölblinger: Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria

PY - 2022

Y1 - 2022

KW - IMMUNE-RELATED RESPONSE

KW - CUTANEOUS MELANOMA

KW - F-18-FDG PET/CT

KW - POOLED ANALYSIS

KW - OPEN-LABEL

KW - IPILIMUMAB

KW - SURVIVAL

KW - PEMBROLIZUMAB

KW - NIVOLUMAB

KW - PHASE-3

U2 - 10.1016/j.ejrad.2021.110107

DO - 10.1016/j.ejrad.2021.110107

M3 - Original Article

C2 - 34922117

SN - 0720-048X

VL - 146

SP - 110107

JO - EUROPEAN JOURNAL OF RADIOLOGY

JF - EUROPEAN JOURNAL OF RADIOLOGY

ER -

Schweighofer-Zwink G, Manafi-Farid R, Kölblinger P , Hehenwarter L, Harsini S, Pirich C et al. Prognostic value of 2-[ 18 F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy . EUROPEAN JOURNAL OF RADIOLOGY . 2022;146:110107. doi: 10.1016/j.ejrad.2021.110107